Physician profile
Robert Bonwetsch
NPI 1801856687
$2,255.57
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,784 · 2020: $451 · 2024: $20.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $283.81 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $277.59 | 2019 | |
| Acadia Pharmaceuticals INC | $134.23 | 2019-2020 | |
| Lundbeck LLC | $124.70 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $116.25 | 2019-2020 | |
| Eisai INC. | $111.19 | 2019-2020 | |
| Genzyme Corporation | $104.25 | 2019 | |
| Boston Scientific Corporation | $92.38 | 2020 | |
| Biogen, INC. | $78.16 | 2019 | |
| Grifols USA, LLC | $73.73 | 2019 | |
| Avanir Pharmaceuticals, INC. | $72.57 | 2019 | |
| Emd Serono, INC. | $56.75 | 2019 | |
| Ge Healthcare | $52.70 | 2019-2020 | |
| Csl Behring | $49.04 | 2019 | |
| Greenwich Biosciences, INC. | $47.98 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $44.81 | 2019-2020 | |
| Livanova USA, INC. | $43.80 | 2019 | |
| Sunovion Pharmaceuticals INC. | $43.65 | 2019 | |
| Lilly USA, LLC | $42.75 | 2019 | |
| Shire North American Group INC | $40.06 | 2019 | |
| Allergan, INC. | $38.55 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $26.59 | 2020 | |
| Alnylam Pharmaceuticals INC. | $24.49 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.48 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $24.18 | 2019 | |
| Kyowa Kirin, INC. | $22.14 | 2020 | |
| Sk Life Science, INC. | $21.47 | 2020 | |
| Neurelis, INC. | $20.92 | 2024 | Valtoco |
| Currax Pharmaceuticals LLC | $18.36 | 2020 | |
| Jazz Pharmaceuticals INC. | $18.13 | 2020 | |
| Mallinckrodt Enterprises LLC | $17.08 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.15 | 2019 | |
| Adlon Therapeutics L.P. | $15.66 | 2019 | |
| Upsher-Smith Laboratories LLC | $15.01 | 2019 | |
| Promius Pharma LLC | $14.04 | 2019 | |
| Assertio Therapeutics, INC. | $13.09 | 2019 | |
| Abbvie INC. | $12.09 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.83 | 2019 | |
| Amgen INC. | $10.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bonwetsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.